RxDoctor Payments Data

Allen Bott, MD

Neurology with Special Qualifications in Child Neurology · Oakland, CANPI 1770577652

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $289,991 of the $371,554 with a category attached, or 78.0%. 20 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 38.6% of the total. Among neurology with special qualifications in child neurology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$371,554in general payments, 2019–2025

Across 563 payments — averaging $659.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$144K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$60K
  • AbbVie$46K
  • Axsome Therapeutics, Inc.$39K
  • Otsuka America Pharmaceutical, Inc.$24K
  • Eisai Inc.$23K
  • plus $36K from 14 others

What the payments were for

  • Consulting fees$47,61813%
  • Speaking & faculty fees$289,99178%
  • Travel & lodging$22,6396%
  • Food & beverage$11,0323%
  • Education$2730%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$371,554 in reported general payments places this provider in the 95th percentile of 216 neurology with special qualifications in child neurology providers in California.

See all neurology with special qualifications in child neurology providers in California

Medicare billing

Part B allowed, 2024
$80,896
Medicare patients
165
Services billed
498

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate51$407,494
NuplazidPimavanserin Tartrate26$119,937
TrintellixVortioxetine Hydrobromide121$104,463
RexultiBrexpiprazole54$95,008
EmsamSelegiline13$53,050
VraylarCariprazine Hcl31$43,742
AuvelityDextromethorphan Hbr/Bupropion44$42,947
Ajovy AutoinjectorFremanezumab-Vfrm25$31,252
UbrelvyUbrogepant17$25,346
CaplytaLumateperone Tosylate14$22,619
NuedextaDextromethorphan Hbr/Quinidine12$19,994
RytaryCarbidopa/Levodopa24$15,340
BelsomraSuvorexant18$10,565
Venlafaxine Hcl ErVenlafaxine Hcl203$7,570
NamzaricMemantine Hcl/Donepezil Hcl12$6,639

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$143,576$407,49451 claims
Acadia Pharmaceuticals IncNuplazid$27$119,93726 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$14,876$104,463121 claims
Otsuka America Pharmaceutical, Inc.Rexulti$23,559$95,00854 claims
AbbVieVraylar, Ubrelvy, Namzaric$46,417$75,72860 claims
Axsome Therapeutics, Inc.Auvelity$39,027$42,94744 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$60,110$22,61914 claims
Avanir Pharmaceuticals, Inc.Nuedexta$25$19,99412 claims
Amneal Pharmaceuticals LLCRytary$30$15,34024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 216 neurology with special qualifications in child neurology providers in California.

Other neurology with special qualifications in child neurology in Oakland

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →